Which of the following is NOT true regarding ipratropium bromide: a. It is a…
- User
Which of the following is NOT true regarding ipratropium bromide:
a. It is a parasympatholytic agent b. It has a long onset of action c. Derived from atropine d. Mechanism of action is via increase of cyclic AMP e. It is a muscarinic receptor
Mark true or false for each option and explain your reason in detail (explain extensively and comprehensively).
- Assistant
Let's go through each option in detail:
a. True. Ipratropium bromide is indeed a parasympatholytic agent (or anticholinergic). This means it inhibits the action of the parasympathetic nervous system. Specifically, it blocks muscarinic receptors, which are a type of acetylcholine receptor found in the parasympathetic nervous system. This blockage inhibits the actions of acetylcholine, a neurotransmitter that mediates various bodily functions including bronchoconstriction. Therefore, by being a parasympatholytic, ipratropium bromide helps in dilating the airways in conditions like COPD and asthma.
b. False. Ipratropium bromide actually has a relatively quick onset of action, not a long one. When administered via inhalation, its effects can begin within minutes. Specifically, its onset of action is generally within 15 to 30 minutes, making it suitable for the relief of acute symptoms in obstructive lung diseases. The misconception might arise when comparing it to other treatments like albuterol (a short-acting beta-agonist), which can act even more quickly. However, in the context of pharmacology, ipratropium's onset is considered relatively fast, not long.
c. True. Ipratropium bromide is indeed derived from atropine. Both atropine and ipratropium are anticholinergic agents. However, ipratropium bromide is a synthetic derivative designed to be more selective for the lungs when inhaled, thus reducing systemic side effects associated with atropine.
d. False. The mechanism of action of ipratropium bromide does not involve the increase of cyclic AMP (cAMP). Instead, it works by blocking muscarinic receptors in the airways. This blockade inhibits the action of acetylcholine on these receptors, which in turn prevents the increase in intracellular calcium that would normally lead to bronchoconstriction. The increase in cAMP is actually a mechanism associated with beta-adrenergic agonists (like albuterol), not with anticholinergic agents like ipratropium bromide.
e. False. Ipratropium bromide is not a muscarinic receptor; it is an antagonist of muscarinic receptors. This means it binds to these receptors without activating them, effectively blocking or inhibiting the action of acetylcholine, which is the natural neurotransmitter that would normally activate these receptors. The confusion might arise from the phrasing, as ipratropium affects muscarinic receptors but is not one itself; it is a molecule designed to interact with these receptors.
In summary, ipratropium bromide is a parasympatholytic agent derived from atropine, with a quick onset of action, that works by blocking muscarinic receptors, not by increasing cAMP. It is an antagonist, not a receptor.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.